Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DexCom, Inc. (DXCM) vs Hasbro, Inc. (HAS) Price & Performance

DexCom, Inc.Trade
Hasbro, Inc.Trade

Price performance (Past 24H)

Key statistics

DexCom, Inc. vs Hasbro, Inc. — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.81B), while Hasbro, Inc. trades at $92.69 (market cap $12.80B). The key difference: DexCom, Inc. is far larger — about 2.5× Hasbro, Inc.'s market cap, and Hasbro, Inc. pays a 3.09% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Hasbro, Inc. for 97 Days on average.

DXCMHAS
Market Cap
$31.81B$12.80B
Volume
2,861,8211,356,688
Sector
HealthConsumer Cyclical
52-Week High
$92.34$105.88
52-Week Low
$54.84$70.95
Typical Hold Time
62 Days97 Days
Enterprise Value
$31.26B$14.99B
Dividend Yield
—3.09%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DexCom, Inc.

DexCom (DXCM) trades at $84.41, showing modest daily gains of 1.22% amid a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $0.70 exceeding expectations of $0.611. Revenue growth remains robust, climbing from $2.9B in 2022 to $4.7B in 2025, while net income margins improved to 17.93%. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.

Wall Street maintains a bullish stance with 81% buy ratings and a $95.07 consensus price target, representing 13% upside potential. Key risks include competitive pressures in CGM markets and reimbursement challenges. The company's strong cash flow generation and expanding market opportunity in diabetes technology support long-term growth prospects despite current technical weakness.

Hasbro, Inc.

Hasbro (HAS) trades at $92.50, up 1.61% today, with a bullish technical outlook and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 20, 2026. Revenue is projected to grow to $5.0B in 2026, with net income rebounding to $794M. The company maintains a solid gross profit margin of 64.41% and positive operating cash flow, though it carries significant long-term debt of $3.38B.

The outlook is positive, driven by earnings momentum and cost-saving initiatives, but risks include high debt levels and competitive pressures. Analyst price targets suggest upside potential, with a consensus target of $107.60. Investors should monitor the upcoming earnings report for confirmation of growth trends and debt management progress.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DXCM
100% Buy0% Sell
Avg holding period · 62 Days
HAS

No sentiment data available yet.

Top news

Latest headlines on both assets

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM →

About Hasbro, Inc.

Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.

Read more on HAS →